Symbols

AARD

Aardvark·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AARD

Aardvark Therapeutics, Inc.

A biopharmaceutical company dedicated to developing drugs for weight loss and metabolic disease treatment

Industry

Pharmaceutical

Established Date

05/17/2017

Listing Date

02/13/2025

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

aardvarktherapeutics.com

Security Type

Common stock

Office address

4370 La Jolla Village Drive, Suite 1050, San Diego, CA 92122

Business

Introduction

Aardvark Therapeutics, Inc., was incorporated in Delaware on May 17, 2017. The company is a clinical-stage biopharmaceutical company that develops small molecule therapies targeting bitter receptors to activate the innate homeostasis pathway in metabolic diseases. Its lead drug candidate, ARD-101, an oral, gut-limited agonist, is being studied for Prader-Willi syndrome-related hyperphagia, and its Phase 3 trial has been voluntarily suspended for data review.

Company Financials

EPS

AARD has released its 2025 Q4 earnings. EPS was reported at -0.81, versus the expected -0.8, missing expectations. The chart below visualizes how AARD has performed over recent quarters, highlighting trends in earnings surprises.